Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis Pubmed



Alsahebfosoul F1 ; Hosseini AZ1 ; Salehi R2 ; Etemadifar M3 ; Esmaeil N4 ; Jamshidian A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  2. 2. Department of Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Tehran, Iran
  3. 3. Neurology Department, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Immunology, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

Source: Iranian Journal of Allergy, Asthma and Immunology Published:2015


Abstract

Soluble forms of nonclassical human leukocyte antigen (HLA)-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS). HLA-G inhibits the effecter function of T cells and natural killer (NK) cells. Also regulatory T cells (Treg) are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and compare it to healthy controls. Patients with RRMS (n=205, mean age=31.32±8.53) and healthy subjects (n=205, mean age=32.2±7.48) were studied. The patients subgrouped to untreated and treated with Interferon beta. Then sHLA-G levels (sHLA-G1 and sHLA-G5) were measured using ELISA method. Treg (CD4+CD25+ Foxp3+) cells in patients who had sHLA-G>10 U/ml were characterized by using flow cytometry. Our data showed that there was no significant differences between RRMS patients and healthy controls in sHLA-G concentration (p>0.05). Treg cell frequencies were higher in the patients who had sHLA-G >10 U/ml compared to healthy subjects (p<0.05). Collectively, there was significant correlation between sHLA-G and frequency of Treg cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has been instrumental in raising frequency of Treg cells in treated patients and could be associated with remission of MS disease. Copyright © Spring 2015, Iran J Allergy Asthma Immunol. All rights reserved.
Related Docs
View other Related Docs
1. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
2. High-Resolution Melting Curve Analysis of Polymorphisms Within Cd58, Cd226, Hla-G Genes and Association With Multiple Sclerosis Susceptibility in a Subset of Iranian Population: A Case–Control Study, Acta Neurologica Belgica (2020)
3. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
4. Evaluation of Lymphocyte Activation Gene3 (Lag-3) on Regulatory T Cells in Patients With Multiple Sclerosis by Intervention Effect of Fingolimod, Journal of Isfahan Medical School (2016)
5. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
6. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
7. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
8. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (70)
Vahid Shaygannejad (53)
Other Related Docs
9. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
10. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
11. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
12. Evaluation of the Prevalence of Anti-Transglutaminase 2 and 6 Antibodies in Patients With Sero-Positive Multiple Sclerosis, Middle East Journal of Digestive Diseases (2024)
13. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
14. Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (Ms) Patients in Vitro, Inflammation (2019)
15. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
16. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
17. The +4259A>C Polymorphism of Tim-3 But Not -1637C>T Polymorphism of Tim-1 Is Associated With Multiple Sclerosis in Isfahan Population, Multiple Sclerosis and Related Disorders (2017)
18. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
19. Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls, Immunological Investigations (2015)
20. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
21. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
22. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
23. The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies, Health Science Reports (2022)
24. Apamin As a Bbb Shuttle and Its Effects on T Cell Population During the Experimental Autoimmune Encephalomyelitis-Induced Model of Multiple Sclerosis, Neurotoxicity Research (2021)
25. Mannose-Binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders, Iranian Journal of Allergy, Asthma and Immunology (2016)
26. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
27. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
28. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
29. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
30. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
31. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
32. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
33. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
34. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
35. An Investigation Into the Association Between Hla-G 14Bp Insertion/Deletion Polymorphism and Multiple Sclerosis Susceptibility, Journal of Neuroimmunology (2016)
36. Can Plasma Exchange Therapy Induce Regulatory T Lymphocytes in Multiple Sclerosis Patients?, Clinical and Experimental Immunology (2012)
37. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
38. Promising Effect of Rapamycin on Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2018)
39. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
40. Association of Killer Cell Immunoglobulin-Like Receptors and Their Cognate Hla Class I Ligands With Susceptibility to Acute Myeloid Leukemia in Iranian Patients, Scientific Reports (2023)
41. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
42. Evaluation of the Prevalence of Bovine Leukemia Virus Dna in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, IJID Regions (2023)
43. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
44. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
45. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
46. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
47. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)
48. Comparing the Frequency of Tim-3 Polymorphism in Multiple Sclerosis Patients With Healthy Controls, Journal of Isfahan Medical School (2015)
49. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
50. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)